China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) EBIT: ¥1,216 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600750 China Resources Jiangzhong Pharmaceutical Co Ltd SHSE:600750
91 GF Score
Price ¥24.70
GF Value ¥21.28
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is China Resources Jiangzhong Pharmaceutical Co EBIT?

China Resources Jiangzhong Pharmaceutical Co SHSE:600750 +4.97% 91 EBIT is ¥1,216 Mil as of Mar. 2026. GuruFocus rates SHSE:600750 with a GF Score™ of 91/100 and a GF Value™ of ¥21.28 (Modestly Overvalued). The stock has 3 warning signs investors should review.

China Resources Jiangzhong Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥361 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1,216 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China Resources Jiangzhong Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 was 25.63%. China Resources Jiangzhong Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 71.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. China Resources Jiangzhong Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.86%.

China Resources Jiangzhong Pharmaceutical Co  (SHSE:600750) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

China Resources Jiangzhong Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1342.94 * ( 1 - 13.47% )/( (4393.148 + 4674.197)/ 2 )
=1162.045982/4533.6725
=25.63 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6880.863 - 1683.557 - ( 804.158 - max(0, 1905.606 - 3428.413+804.158))
=4393.148

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7159.996 - 1547.325 - ( 938.474 - max(0, 1869.989 - 3471.623+938.474))
=4674.197

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

China Resources Jiangzhong Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1443.12/( ( (1887.533 + max(253.21, 0)) + (1908.072 + max(-46.392, 0)) )/ 2 )
=1443.12/( ( 2140.743 + 1908.072 )/ 2 )
=1443.12/2024.4075
=71.29 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(404.902 + 454.078 + 1298.398) - (1683.557 + 0 + 220.611)
=253.21

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(487.507 + 408.209 + 926.769) - (1547.325 + 0 + 321.552)
=-46.392

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

China Resources Jiangzhong Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1216.083/15467.618
=7.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Jiangzhong Pharmaceutical Co EBIT Related Terms

China Resources Jiangzhong Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for China Resources Jiangzhong Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Jiangzhong Pharmaceutical Co EBIT Chart

China Resources Jiangzhong Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 626.60 757.66 923.10 1,027.32 1,214.53

China Resources Jiangzhong Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 359.23 344.50 220.69 290.12 360.78

SHSE:600750 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Jiangzhong Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Resources Jiangzhong Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Jiangzhong Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China Resources Jiangzhong Pharmaceutical Co's EV-to-EBIT falls into.


SHSE:600750
91GF Score
China Resources Jiangzhong Pharmaceutical Co Ltd SHSE:600750
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Jiangzhong Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,216 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥1,216 Mil mean?
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) has a EBIT of ¥1,216 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Resources Jiangzhong Pharmaceutical Co.
Is China Resources Jiangzhong Pharmaceutical Co's EBIT too high?
China Resources Jiangzhong Pharmaceutical Co's current EBIT is ¥1,216 Mil. Overall, China Resources Jiangzhong Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Jiangzhong Pharmaceutical Co's EBIT compare to ZTS and UTHR?
China Resources Jiangzhong Pharmaceutical Co's EBIT of ¥1,216 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Resources Jiangzhong Pharmaceutical Co. China Resources Jiangzhong Pharmaceutical Co's current EBIT is ¥1,216 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Jiangzhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥21.28, compared to a current price of ¥24.70 — trading 16.1% above its estimated fair value. The current EBIT is ¥1,216 Mil. China Resources Jiangzhong Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For China Resources Jiangzhong Pharmaceutical Co (SHSE:600750), the current EBIT is ¥1,216 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥24.70 is trading 16.1% above its estimated GF Value™ of ¥21.28. GuruFocus considers China Resources Jiangzhong Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600750:

  • EBIT: ¥1,216 Mil
  • GF Value™: ¥21.28 vs. price of ¥24.70 (16.1% above fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Jiangzhong Pharmaceutical Co Business Description

Address No. 788, Torch Avenue, High-tech Zone, Jiangxi Province, Nanchang, CHN, 330096
China Resources Jiangzhong Pharmaceutical Co Ltd is engaged in the research and development, production, and sale of over-the-counter pharmaceuticals and health-related products, including functional foods. Its business activities also include the production and sale of proprietary Chinese medicines and chemical drugs.
91GF Score

Get the complete analysis for SHSE:600750

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.70
Price
¥21.28
GF Value